PL2678037T3 - Rozgałęziony łącznik do koniugatów białko-lek. - Google Patents

Rozgałęziony łącznik do koniugatów białko-lek.

Info

Publication number: PL2678037T3
Authority: PL; Poland
Prior art keywords: drug conjugates; protein drug; branched linker; linker; branched
Prior art date: 2011-02-25

Application number

PL12706239T

Other languages

English (en)

Inventor

Laurent Ducry

Bernhard Stump

Wong, (Wang) Heilam (Harry)

Jin She (Jacky)

Gayle Phillips

Original Assignee

Lonza Ag

Lonza Guangzhou Nansha Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-25

Filing date

2012-02-23

Publication date

2015-05-29

2012-02-23 Application filed by Lonza Ag, Lonza Guangzhou Nansha Ltd filed Critical Lonza Ag

2015-05-29 Publication of PL2678037T3 publication Critical patent/PL2678037T3/pl

Links

239000001990 protein-drug conjugate Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL12706239T 2011-02-25 2012-02-23 Rozgałęziony łącznik do koniugatów białko-lek. PL2678037T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
CN2011071287		2011-02-25
CN2011077863		2011-08-01
CN2011081857		2011-11-07
PCT/EP2012/053039 WO2012113847A1 (en)	2011-02-25	2012-02-23	Branched linker for protein drug conjugates
EP12706239.6A EP2678037B1 (en)	2011-02-25	2012-02-23	Branched linker for protein drug conjugates

Publications (1)

Publication Number	Publication Date
PL2678037T3 true PL2678037T3 (pl)	2015-05-29

Family

ID=45771806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12706239T PL2678037T3 (pl)	2011-02-25	2012-02-23	Rozgałęziony łącznik do koniugatów białko-lek.

Country Status (8)

Country	Link
US (2)	US10294270B2 (pl)
EP (1)	EP2678037B1 (pl)
JP (3)	JP5559439B2 (pl)
DK (1)	DK2678037T3 (pl)
ES (1)	ES2531471T3 (pl)
HK (2)	HK1186668A1 (pl)
PL (1)	PL2678037T3 (pl)
WO (1)	WO2012113847A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10294270B2 (en) *	2011-02-25	2019-05-21	Lonza Ltd	Branched linker for protein drug conjugates
EP2968599A4 (en)	2013-03-14	2016-11-09	Albany Molecular Res Inc	LIGAND THERAPEUTIC ACID JUGATES AND LINKERS ON SILICON BASE
PT2968440T (pt)	2013-03-15	2019-07-31	Zymeworks Inc	Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos
CA2913011A1 (en)	2013-05-31	2014-12-04	Genentech, Inc.	Anti-wall teichoic antibodies and conjugates
US9803002B2 (en)	2013-05-31	2017-10-31	Genentench, Inc.	Anti-wall teichoic antibodies and conjugates
CA2910029A1 (en)	2013-05-31	2014-12-04	Genentech, Inc.	Anti-wall teichoic antibodies and conjugates
MX2016001862A (es)	2013-08-12	2016-08-03	Genentech Inc	Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
WO2015038426A1 (en)	2013-09-13	2015-03-19	Asana Biosciences, Llc	Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
IL293071A (en) *	2013-10-15	2022-07-01	Seagen Inc	Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
JP6980384B2 (ja)	2013-12-16	2021-12-15	ジェネンテック，インコーポレイテッド	１−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
WO2015095301A2 (en)	2013-12-17	2015-06-25	Irm Llc	Cytotoxic peptides and conjugates thereof
CA2935077C (en)	2013-12-27	2022-03-15	Geoffrey C. Winters	Sulfonamide-containing linkage systems for drug conjugates
RU2714933C2 (ru)	2013-12-27	2020-02-21	Займворкс Инк.	Конъюгаты var2csa-лекарственное средство
WO2015189791A1 (en)	2014-06-13	2015-12-17	Novartis Ag	Auristatin derivatives and conjugates thereof
US10786578B2 (en)	2014-08-05	2020-09-29	Novartis Ag	CKIT antibody drug conjugates
DK3194421T3 (da)	2014-09-17	2022-02-14	Zymeworks Inc	Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
SG11201701342XA (en) *	2014-10-24	2017-03-30	Polytherics Ltd	Conjugates and conjugating reagents
WO2016071856A1 (en)	2014-11-06	2016-05-12	Novartis Ag	Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
RU2731055C2 (ru)	2014-12-03	2020-08-28	Дженентек, Инк.	Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
MX2017007231A (es)	2014-12-03	2017-11-08	Genentech Inc	Conjugados de rifamicina y anticuerpos contra el staphylococcuss aureus y usos de estos.
EP3878861B1 (en)	2015-02-16	2025-05-07	Lonza Ltd.	Cl and/or ch1 mutated antibodies for drug conjugation
WO2016203432A1 (en)	2015-06-17	2016-12-22	Novartis Ag	Antibody drug conjugates
EP3165532B1 (en)	2015-11-03	2018-12-19	Industrial Technology Research Institute	Auristatin derivatives, linker-drugs and ligand-drug conjugates
US11793880B2 (en)	2015-12-04	2023-10-24	Seagen Inc.	Conjugates of quaternized tubulysin compounds
SG10202010590UA (en)	2015-12-04	2020-12-30	Seattle Genetics Inc	Conjugates of quaternized tubulysin compounds
EA201892040A1 (ru)	2016-03-25	2019-04-30	Сиэтл Дженетикс, Инк.	Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
EP3464280B1 (en)	2016-06-06	2021-10-06	F. Hoffmann-La Roche AG	Silvestrol antibody-drug conjugates and methods of use
EP3600443A1 (en)	2017-03-24	2020-02-05	Seattle Genetics, Inc.	Process for the preparation of glucuronide drug-linkers and intermediates thereof
CN112188902A (zh)	2018-05-29	2021-01-05	百时美施贵宝公司	用于前药和缀合物的经修饰的自消灭部分以及使用和制造方法
CN113164414A (zh)	2018-10-24	2021-07-23	纳维托制药有限公司	多晶型化合物和其用途
WO2025040820A1 (en)	2023-08-23	2025-02-27	Granular Therapeutics Limited	Anti-cd203c antibody conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6214345B1 (en)	1993-05-14	2001-04-10	Bristol-Myers Squibb Co.	Lysosomal enzyme-cleavable antitumor drug conjugates
US6759509B1 (en)	1996-11-05	2004-07-06	Bristol-Myers Squibb Company	Branched peptide linkers
ES2154590B1 (es)	1999-05-20	2001-11-01	Lipotec Sa	Procedimiento de sintesis de peptidos en fase solida
ES2649550T3 (es) *	2005-07-18	2018-01-12	Seattle Genetics, Inc.	Conjugados del enlazador fármaco de beta-glucurónido
US7750116B1 (en)	2006-02-18	2010-07-06	Seattle Genetics, Inc.	Antibody drug conjugate metabolites
WO2008053479A1 (en) *	2006-10-30	2008-05-08	Ramot At Tel Aviv University Ltd.	Self-immolative polymers
US10294270B2 (en) *	2011-02-25	2019-05-21	Lonza Ltd	Branched linker for protein drug conjugates

2012
- 2012-02-23 US US14/001,237 patent/US10294270B2/en active Active
- 2012-02-23 DK DK12706239T patent/DK2678037T3/en active
- 2012-02-23 JP JP2013554887A patent/JP5559439B2/ja active Active
- 2012-02-23 PL PL12706239T patent/PL2678037T3/pl unknown
- 2012-02-23 EP EP12706239.6A patent/EP2678037B1/en active Active
- 2012-02-23 WO PCT/EP2012/053039 patent/WO2012113847A1/en active Application Filing
- 2012-02-23 ES ES12706239.6T patent/ES2531471T3/es active Active
2013
- 2013-12-23 HK HK13114160.0A patent/HK1186668A1/xx unknown
2014
- 2014-04-08 JP JP2014079529A patent/JP6169520B2/ja active Active
2015
- 2015-12-18 JP JP2015247482A patent/JP2016128417A/ja not_active Withdrawn
2016
- 2016-02-18 HK HK16101713.6A patent/HK1213773A1/zh unknown
2018
- 2018-03-23 US US15/933,800 patent/US10214560B2/en active Active

Also Published As

Publication number	Publication date
JP2016128417A (ja)	2016-07-14
JP2014169298A (ja)	2014-09-18
JP2014507439A (ja)	2014-03-27
EP2678037B1 (en)	2014-12-03
US20130324706A1 (en)	2013-12-05
JP5559439B2 (ja)	2014-07-23
EP2678037A1 (en)	2014-01-01
HK1213773A1 (zh)	2016-07-15
WO2012113847A1 (en)	2012-08-30
US20180258136A1 (en)	2018-09-13
US10214560B2 (en)	2019-02-26
JP6169520B2 (ja)	2017-07-26
ES2531471T3 (es)	2015-03-16
HK1186668A1 (en)	2014-03-21
US10294270B2 (en)	2019-05-21
DK2678037T3 (en)	2015-03-09

Publication	Publication Date	Title
HK1213773A1 (zh)	2016-07-15	用於蛋白質藥物偶聯物的支鏈聯接體
IL263973B (en)	2020-05-31	Protein-polymer-drug conjugates
HK1221153A1 (zh)	2017-05-26	抗體-藥物綴合物
HK1208186A1 (en)	2016-02-26	Drug protein conjugates
HK1208187A1 (en)	2016-02-26	Drug protein conjugates
EP2723393A4 (en)	2015-02-25	EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
HK1210477A1 (en)	2016-04-22	Antibody drug conjugate
IL236323A0 (en)	2015-02-26	Drug conjugates of anti–cd70 antibody
HK1196257A1 (zh)	2014-12-12	-抗體結合物
HK1189031A1 (zh)	2014-05-23	用於細胞內遞送核酸的小分子綴合物
HK1201727A1 (en)	2015-09-11	Anticancer fusion protein
SG10201604667YA (en)	2016-07-28	Pharmaceutical preparation
SI2661496T1 (sl)	2017-09-29	Fuzijski protein proti raku
EP2683737A4 (en)	2014-09-03	EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
EP2575887A4 (en)	2015-01-14	CONJUGATES OF OPTIMIZED MEDICINES
HK1201848A1 (en)	2015-09-11	Anticancer fusion protein
GB201105298D0 (en)	2011-05-11	Pharmaceutical preparation
ZA201308597B (en)	2014-12-23	Anticancer fusion protein
EP2731610A4 (en)	2014-12-10	PHARMACEUTICAL COMBINATION
ZA201304462B (en)	2014-02-26	Novel conjugates for targeted drug delivery
PL2691119T3 (pl)	2019-01-31	Preparat farmaceutyczny
HK1203150A1 (en)	2015-10-23	Improved processes for preparing peptide conjugates and linkers
EP2768488A4 (en)	2015-04-15	TWO-PHASE PHARMACEUTICAL DELIVERY SYSTEM
GB201119796D0 (en)	2011-12-28	Pharmaceutical comopounds